GMED
Globus Medical, Inc.
GMED has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has a slight edge over GMED overall, supported by stronger modeled upside.
GMED Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
GMED's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GMED PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $72.30 | — |
| Current | 18x | $72.30 | — |
| Cheap | 26x | $106 | +46% |
| Fair | 41x | $166 | +129% |
| Expensive | 70x | $283 | +291% |
Historical ranges are pointers, not guarantees.
GMED has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GMED Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect GMED's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over GMED on the outlook, with more favorable revenue expectations.
GMED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.18 | +28% |
| Q3 2026 | $4.05 | +31% |
| Q2 2026 | $3.89 | +50% |
| Q1 2026 | $4.28 | +219% |
| Q4 2025 | $3.92 | +423% |
| Q3 2025 | $3.10 | +349% |
| Q2 2025 | $2.60 | +713% |
| Q1 2025 | $1.34 | +103% |
| Q4 2024 | $0.75 | -37% |
GMED earned $4.05 per share over the past year, up 31% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
GMED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $763.7M | -0.7% |
| Q2 2026 | $789.6M | +5.9% |
| Q1 2026 | $759.9M | +27% |
| Q4 2025 | $826.4M | +26% |
| Q3 2025 | $769M | +23% |
| Q2 2025 | $745.3M | +18% |
| Q1 2025 | $598.1M | -1.4% |
| Q4 2024 | $657.3M | +6.6% |
GMED's revenue is growing: $764M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +5.4 points |
| Q2 2026 | 23% | +13 points |
| Q1 2026 | 20% | +3.6 points |
| Q4 2025 | 20% | +11 points |
| Q3 2025 | 18% | +10 points |
| Q2 2025 | 10% | +2.3 points |
| Q1 2025 | 16% | +15 points |
| Q4 2024 | 9.2% | +7.5 points |
GMED's operating margin was 23% last quarter, up 5.4 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GMED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GMED on profitability, with a higher operating margin.
GMED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $224.8M | +5.1% |
| Q2 2026 | $176.6M | +464% |
| Q1 2026 | $162.7M | +15% |
| Q4 2025 | $202.4M | +4.7% |
| Q3 2025 | $213.9M | +32% |
| Q2 2025 | $31.3M | +18% |
| Q1 2025 | $141.2M | +493% |
| Q4 2024 | $193.2M | +136% |
GMED has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GMED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -1.4M shares |
| 1 year | +0.5% | +623K shares |
| 3 years | +18% | +20.8M shares |
| 5 years | +30% | +31.6M shares |
| Available history | +33% | +34M shares |
GMED has 136M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $142.9M |
| Q2 2026 | $136.1M |
| Q1 2026 | — |
| Q4 2025 | $45M |
| Q3 2025 | $40M |
| Q2 2025 | $25M |
| Q1 2025 | $190.5M |
| Q4 2024 | $1M |
GMED spent $324M buying back its own shares over the past year, up 26% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GMED on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GMED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
GMED has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GMED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 15.8 | Oversold |
GMED's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GMED PE vs Healthcare Sector
| Metric | GMED | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 0 | 29 | 29 pts below |
GMED has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GMED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $75.5 | 4.3% below |
| 20 week MA | $78.0 | 7.3% below |
| 50 week MA | $83.6 | 14% below |
| 100 week MA | $76.5 | 5.5% below |
| 200 week MA | $68.5 | 5.6% above |
GMED has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GMED on trend strength, trading above more of its moving averages.
GMED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $65.3 | +11% |
| 2021 | $65.3 | $72.2 | +11% |
| 2022 | $72.2 | $73.9 | +2.3% |
| 2023 | $73.9 | $53.3 | -28% |
| 2024 | $53.3 | $83.6 | +57% |
| 2025 | $83.6 | $88.4 | +5.8% |
| 2026 YTD | $88.4 | $72.3 | -18% |
GMED has finished higher in five of the last six years. It's down 18% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GMED on returns for 2026, with the stronger performance.